Follow The Filings

TECX Tectonic Therapeutic Inc.

Health Care, filed as TECTONIC THERAPEUTIC INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 exit

In 2026 Q2 James Silverman sold out of Tectonic Therapeutic.

Who owns TECX

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management exited 2026 Q2 Last 2026 Q1 0.50% Exit −0.50% 123,000 $3.8M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TECX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TECX insider trades
  • $182K bought by 2 insiders
  • None no sales outside a trading plan
  • $651K sold by 2 insiders under 10b5-1 plans
  1. Peter McNamara Chief Scientific Officer
    Planned sale
    $12K 536 shares at $23.04 1% of stake
    Traded Sep 30 Filed Oct 2
  2. Peter McNamara Chief Scientific Officer
    Planned sale
    $1,570 43 shares at $36.52 0.1% of stake
    Traded Aug 25 Filed Aug 26
  3. Peter McNamara Chief Scientific Officer
    Planned sale
    $1,505 43 shares at $35.00 0.1% of stake
    Traded Aug 12 Filed Aug 14
  4. Peter McNamara Chief Scientific Officer
    Planned sale
    $6,020 172 shares at $35.00 0.3% of stake
    Traded Jun 30 Filed Jul 1
  5. Marcella K. Ruddy Chief Medical Officer
    Planned sale
    $32K 1,065 shares at $30.00 1.5% of stake
    Traded May 4 Filed May 6
  6. Marcella K. Ruddy Chief Medical Officer
    Planned sale
    $31K 1,000 shares at $31.05 1.4% of stake
    Traded Apr 1 Filed Apr 3
  7. Marcella K. Ruddy Chief Medical Officer
    Planned sale
    $300K 10,000 shares at $30.00 13% of stake
    Traded Mar 6 Filed Mar 9
  8. Peter McNamara Chief Scientific Officer
    Planned sale
    $189K 6,262 shares at $30.17 10% of stake
    Traded Mar 6 Filed Mar 9
  9. Peter McNamara Chief Scientific Officer
    Planned sale
    $78K 3,299 shares at $23.53 5.3% of stake
    Traded Mar 3–4 Filed Mar 5
  10. Alise Reicin CEO
    Buy
    $53K 2,500 shares at $21.10 +2% to stake
    Traded Feb 11 Filed Mar 5
  11. Daniel Lochner CFO
    Buy
    $130K 6,000 shares at $21.61 +23% to stake
    Traded Feb 10 Filed Feb 11

Also filed in the last 12 months, not counted as buying or selling: 11 share withholdings for taxes, 8 option exercises, and 5 stock grants.

Congress

No member of Congress reported trading TECX in the last three years. 1 member listed it in 2025 annual reports.

All Congress trades

SEC filings

Recent issuer filings from EDGAR, 9 shown.

Filed Form Detail Links
8-K 8.01,9.01
8-K 2.02,9.01
10-Q
8-K 5.07,8.01,9.01
10-Q
8-K 2.02,9.01
DEF 14A
DEFA14A
8-K 5.02,7.01,9.01

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income $12.16M -$57.98M -$74.15M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $100.26M $146.86M $257.36M
Total non-current assets * $0.832M $6.05M $3.68M
Total assets $101.09M $152.9M $261.04M
Total current liabilities $6.35M $11.61M $9.67M
Total non-current liabilities * $0.00 $519,000 $43,000
Total equity $94.74M $140.78M $251.33M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$63.19M -$59.08M -$60.08M
Cash from investing $85.08M -$0.156M -$0.138M
Cash from financing -$16.03M $171.71M $173.36M
Net change in cash $5.86M $112.47M $113.04M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.